col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


45 Results       Page 1

 [1] 
SAGE Publications: Multiple Sclerosis Journal
  original article Date Title Authors   All Authors
1 [GO] 2022―Nov―28 T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy Anthony T Reder, Olaf Stuve, Stephanie K Tankou, Thomas P Leist
2 [GO] 2022―Jul―13 A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database Jee-Eun Kim, Jin Park, Tae-Jin Song
3 [GO] 2022―Jun―28 Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study Federica Magnè, Maria Cellerino, Elisa Balletto, Kenda Aluan, Matilde Inglese, Malgorzata Mikulska, Matteo Bassetti
4 [GO] 2022―Jun―23 Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, Maria Teresa Ferrò, Alice Laroni, Eleonora Cocco, et al. (+23)
5 [GO] 2022―May―19 Two years of COVID-19 in the MS community: What have we learnt so far? Ana Zabalza, Alan J Thompson, Xavier Montalban
6 [GO] 2022―May―18 Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis Tatjana Schwarz, Carolin Otto, Terry C Jones, Florence Pache, Patrick Schindler, Moritz Niederschweiberer, et al. (+4)
7 [GO] 2022―Apr―27 Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases? Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, Agustín Pappolla, Paula Tagliani, Samuel López-Maza, et al. (+37)
8 [GO] 2022―Apr―27 Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study Giovanna S Manzano, Dylan R Rice, Eric C Klawiter, Marcelo Matiello, Rebecca L Gillani, Shahamat S Tauhid, et al. (+2)
9 [GO] 2022―Feb―12 Clinical commentary MSJ-21-064 MOG antibody-associated longitudinal extensive myelitis after Oxford-Astra Zeneca’s COVID-19 vaccination Sarah Wright
10 [GO] 2022―Jan―07 Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions Jeffrey A Cohen, Robert A Bermel, Cynthia I Grossman, Carrie M Hersh, Megan Hyland, Ellen M Mowry, et al. (+10)
11 [GO] 2021―Dec―21 Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica Edouard Januel, Jérôme De Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, Julie Pique, et al. (+7)
12 [GO] 2021―Dec―21 MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination Larissa Dams, Markus Kraemer, Jana Becker
13 [GO] 2021―Nov―16 Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients Zoé LE van Kempen, Joep Killestein, Hans-Peter Hartung
14 [GO] 2021―Oct―01 Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study Gabriel Bsteh, Sophie Dürauer, Hamid Assar, Harald Hegen, Bettina Heschl, Fritz Leutmezer, et al. (+10)
15 [GO] 2021―Oct―01 Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients Zoya G Georgieva, Rainer Dӧffinger, Dinakantha Kumararatne, Alasdair J Coles, Claire McCarthy
16 [GO] 2021―Sep―30 Demyelinating disorders following COVID-19 vaccination Marcello Moccia
17 [GO] 2021―Sep―30 ADEM after ChAdOx1 nCoV-19 vaccine: A case report Virginia Rinaldi, Gianmarco Bellucci, Andrea Romano, Alessandro Bozzao, Marco Salvetti
18 [GO] 2021―Aug―13 SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action? Paulus S Rommer, Gabriel Bsteh, Thomas Berger, Uwe Klaus Zettl
19 [GO] 2021―Jul―30 SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study Maria Pia Sormani, Irene Schiavetti, Doriana Landi, Luca Carmisciano, Nicola De Rossi, Cinzia Cordioli, et al. (+15)
20 [GO] 2021―Jul―27 COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey Lauren Uhr, Farrah J Mateen
21 [GO] 2021―Jul―09 Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic Zoë YGJ van Lierop, Alyssa A Toorop, Wouter JC van Ballegoij, Tom BG Olde Dubbelink, Eva MM Strijbis, Brigit A de Jong, et al. (+6)
22 [GO] 2021―Jul―02 Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry Tim Spelman, Lars Forsberg, Kyla McKay, Anna Glaser, Jan Hillert
23 [GO] 2021―Jun―08 Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient Bianca Weinstock-Guttman, Dejan Jakimovski
24 [GO] 2021―Jun―04 Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register Afagh Garjani, Rachael Hunter, Graham R Law, Rodden M Middleton, Katherine A Tuite-Dalton, Ruth Dobson, et al. (+9)
25 [GO] 2021―Apr―15 COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 Anat Achiron, Mark Dolev, Shay Menascu, Daniela-Noa Zohar, Sapir Dreyer-Alster, Shmuel Miron, et al. (+9)
26 [GO] 2021―Mar―25 Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey Emilio Portaccio, Mattia Fonderico, Bernhard Hemmer, Tobias Derfuss, Bruno Stankoff, Krzysztof Selmaj, et al. (+2)
27 [GO] 2021―Feb―02 Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis
28 [GO] 2020―Nov―18 COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments Alice Laroni, Irene Schiavetti, Maria Pia Sormani, Antonio Uccelli
29 [GO] 2020―Oct―16 Lymphocyte counts and the risk of COVID-19 in people with MS Nikos Evangelou, Afagh Garjani
30 [GO] 2020―Oct―16 Response to letter ‘Lymphocyte counts and the risk of COVID-19 in people with MS’ Floor C Loonstra, Zoé LE van Kempen, Eva M Strijbis, Joep Killestein, Elske Hoitsma, Jop P Mostert
31 [GO] 2020―Sep―14 Response of the multiple sclerosis community to COVID-19 Olga Ciccarelli, Jeffrey A Cohen, Alan Thompson
32 [GO] 2020―Sep―10 COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary Cristina Valencia-Sanchez, Eoin P Flanagan
33 [GO] 2020―Sep―10 COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? Diogo Goulart Corrêa, Fabiana Cavalcanti de Souza Lima, Daniel da Cruz Bezerra, Antônio Carlos Coutinho, Luiz Celso Hygino da Cruz
34 [GO] 2020―Aug―17 MS, pregnancy and COVID-19 Charmaine Yam, Vilija Jokubaitis, Kerstin Hellwig, Ruth Dobson
35 [GO] 2020―Aug―10 Multiple sclerosis management during the COVID-19 pandemic Brandon P Moss, Kedar R Mahajan, Robert A Bermel, Kelsey Hellisz, Le H Hua, Timothy Hudec, et al. (+20)
36 [GO] 2020―Aug―07 COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? Wallace J Brownlee
37 [GO] 2020―Aug―07 Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient Hannah Wurm, Kate Attfield, Astrid KN Iversen, Ralf Gold, Lars Fugger, Aiden Haghikia
38 [GO] 2020―Aug―07 COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment Rick Dersch, Thomas Wehrum, Sebastian Fähndrich, Monika Engelhardt, Sebastian Rauer, Benjamin Berger
39 [GO] 2020―Jul―14 COVID-19 in multiple sclerosis: The Dutch experience Floor C Loonstra, Elske Hoitsma, Zoé LE van Kempen, Joep Killestein, Jop P Mostert
40 [GO] 2020―Jul―14 COVID-19 in people with multiple sclerosis: A global data sharing initiative Liesbet M Peeters, Tina Parciak, Clare Walton, Lotte Geys, Yves Moreau, Edward De Brouwer, et al. (+42)
41 [GO] 2020―Jun―22 COVID-19 will change MS care forever - Commentary SC Krieger
42 [GO] 2020―Jun―22 COVID-19 will change MS care forever - No Paolo Preziosa, Maria A Rocca, Massimo Filippi
43 [GO] 2020―Jun―22 COVID-19 will change MS care forever - Yes Virginia Meca-Lallana
44 [GO] 2020―Jun―19 Keeping standards of multiple sclerosis care through the COVID-19 pandemic Jaume Sastre-Garriga, Mar Tintoré, Xavier Montalban
45 [GO] 2020―May―28 Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression Tiziana Carandini, Anna Margherita Pietroboni, Luca Sacchi, Milena Alessandra De Riz, Mattia Pozzato, Andrea Arighi, et al. (+4)
 [1] 

45 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.006 sec